RE: Conference callI have to disagree.... I think the implications to Prometic of a major fractionator aligning with or taking over Hemosol would be huge. I agree that the monetary aspects arent immediate although there is the issue of the next milestone payment due in a reasonably short period of time. Obviously all of that becomes much more secure with a larger partner as does the likelihood of success of taking the whole project to commercialization.
To me the much bigger issue is the message to the other large COHN based fractionators that the industry is moving in the direction of the new technology... Cascade... Its been a mexican standoff up until now because of the huge capital investment that the Bayers, Baxters and CSL's have in their current plants. ( not to mention the issue of having to implement the new technology in those existing plants and all of the associated regulatory requirements and disruption.
In my mind, the fractionator that makes the move on HEMOSOL will have a huge advantage over the others.... The immediate value impact is huge... Think about it... DOUBLE the output from the SAME Plasma input and superior purity. In an environment of huge price inflation for stuff like IGG, Factor 8 and other components.. the math is way too easy.
From what I can gather, the Fractionation Conference really drove home to the industry the fact that the Cascade process is ready to go and is becoming very real. Apparently it made quite a stir.
Ironically.... I think Hemosol is great value at these levels and could easilly double as this JV / Takeover becomes real.
I am very encouraged in all respects in terms of the implications to Prometic. Imagine solely what a HMSL / Large Fractionator JV / Takeover does to the other groups that are in discussions with Prometic about Cascade licensing !